Zobrazeno 1 - 10
of 1 749
pro vyhledávání: ''
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A
Autor:
Alexander Stein, Maurice Michel, Jens U. Marquardt, Helge Schroeder, Oliver Waidmann, Marcus-Alexander Woerns, Arndt Weinmann, Markus Moehler, Martin Maenz, Joseph Tintelnot, Friedrich Foerster, Joerg Trojan
Publikováno v:
Future Oncology. 17:3309-3319
Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A convent
Autor:
Bingshu E. Chen, Lois E. Shepherd, Harriet Richardson, Donna E. Reece, Christopher P. Venner, Bethany Monteith, Joe Pater, Rodger E. Tiedemann, Vishal Kukreti, Matthew C. Cheung, Jill Dudebout, Hope Yen, Marc Lalancette, Chai Phua, Max Sherry, Annette E. Hay, Engin Gul, Vincent Castonguay, Sita D. Bhella
Publikováno v:
European Journal of Haematology. 107:333-342
Background The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020). The MYX.1 phase II trial showed that high-dose weekly carfilzomib, cyclophosphamide, and dexame
Autor:
Cheng Yuan Peng, Hadas Dvory-Sobol, Sophia Lu, Peter Buggisch, Wan-Long Chuang, Anuj Gaggar, Christophe Moreno, Alessandra Mangia, Anu Osinusi, Luigi Biancone, Marianne Camargo, Meghan E. Sise, Tsung Hui Hu, Chen-Hua Liu, Brian J. Kirby, Wei Wen Su, Robert H. Hyland
Publikováno v:
American Journal of Gastroenterology. 116:1924-1928
Introduction We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis. Methods Primary efficacy end point was sustained virologic response 12 weeks after treatment. Pr
Autor:
Jie Qiao, Dongping Lin, Xiaoman Chen, Jing Sun, Lin Ye, Boren Jiang, Xiaofeng Tao, Qing Li, Chenfang Zhu, Ziyang Shao, Chunhua Sui, Yingli Lu, Ping Xiong, Hualing Zhai, Buatikamu Abudukerimu, Yubo Ma, Mengda Jiang, Bing Han, Ningjian Wang, Huifang Zhou, Qin Li
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1734-1746 (2021)
Clinical and Translational Science
Clinical and Translational Science
Thyroid‐associated ophthalmopathy (TAO) is a serious, progressive, vision‐threatening and difficult‐to‐treat organ‐specific autoimmune disease. The course, therapeutic effects and prognosis of moderate to severe TAO vary greatly. High‐dos
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Rickard Sandin, Arlene Reisman, Jean Paty, Yi-Long Wu, Jesus Corral, R. Linke, Seiji Niho, Tony Mok, Maria Rita Migliorino, Adam Pluzanski, Ki Hyeong Lee, Kazuhiko Nakagawa, Xiangdong Zhou, Ying Cheng, Oren Meyers
Publikováno v:
Future Oncology. 17:783-794
Aim: Patient-reported symptoms, functioning and overall quality of life (QoL) were compared between dacomitinib and gefitinib in ARCHER 1050. Patients & methods: Patients (n = 448) with advanced EGFR mutation-positive non-small-cell lung cancer compl
Autor:
Keigo Makino, Hiroshi Ishii, Akihito Tsuji, Masato Ozaka, Makoto Ueno, Shingo Kobayashi, Manabu Muto, Daisuke Sakai, Yoshito Komatsu, Masafumi Ikeda, Nobumasa Mizuno, Akira Fukutomi, Toshikazu Moriwaki, Yousuke Nakai, Masayuki Furukawa, Takeshi Kajiwara, Akio Katanuma, Chigusa Morizane, Yuji Negoro, Masahiro Tsuda, Satoshi Shimizu, Junji Furuse, Noriko Nemoto
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 2088-2099 (2021)
Cancer Medicine
Cancer Medicine
Purpose Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S‐1.
Autor:
Huili Wang, Loren S. Michel, Richard J. Wong, Vatche Tchekmedyian, Daphna Y. Gelblum, Lara Dunn, Alisa Rybkin, Bhuvanesh Singh, Kenneth K.-S. Ng, Jung Julie Kang, Wanqing Iris Zhi, Marc Cohen, Snehal G. Patel, C. Jillian Tsai, Juliana Eng, Ian Ganly, James Vincent Fetten, Nader Mohammed, Eric J. Sherman, Stephanie Lobaugh, Yao Yu, Alan L. Ho, Luc G. T. Morris, David G. Pfister, Jay O. Boyle, Sean McBride, Anna Lee, Jennifer R. Cracchiolo, Nancy Y. Lee, Ming Fan, Zhigang Zhang, S. Kitpanit, Kaveh Zakeri, Linda Chen, Nadeem Riaz
Publikováno v:
Int J Cancer
High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m2 × 1 day, every 3 weeks) cisplatin administration at the beginning of the
Autor:
Kazutaka Sunami, Kazuyuki Suzuki, Kazuyuki Shimizu, Kenshi Suzuki, Akio Maki, Morio Matsumoto, Fumika Shimada
Publikováno v:
Acta Haematol
Introduction: Panobinostat, bortezomib, and dexamethasone combination therapy demonstrated progression-free survival (PFS) benefit over bortezomib and dexamethasone alone in the PANORAMA-1 study in relapsed/refractory multiple myeloma (MM). Here, we